Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H M Prince

Showing results (101-110 of 151) with videos related to

Pageof 16
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1996
Intensive therapy and autotransplant for patients with an incomplete response to front-line therapy for lymphomaH M Prince, M Crump, K Imrie, et al.
Leukemia & Lymphoma|December 29, 2004
A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphomaJ J Biagi, K E Herbert, C Smith, et al.
Bone Marrow Transplantation|March 14, 2003
Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastimL B To, J Bashford, S Durrant, et al.
Blood|September 6, 2001
Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemiaB J Huntly, A G Reid, A J Bench, et al.
Gene Therapy|April 30, 2010
Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotypeP Neeson, A Shin, K M Tainton, et al.
Cytotherapy|May 15, 2002
CliniMACS CD34-selected cells to support multiple cycles of high-dose therapyH M Prince, D Wall, D Rischin, et al.
Annals of the Rheumatic Diseases|October 14, 2011
Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohortSiri Lillegraven, Femke H M Prince, Nancy A Shadick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2015
Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphomaS Horwitz, B Coiffier, F Foss, et al.
British Journal of Haematology|March 1, 1996
The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groupsH M Prince, K Imrie, M Crump, et al.
Leukemia|February 7, 2013
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignanciesD J DeAngelo, A Spencer, K N Bhalla, et al.
Pageof 16

Showing results (101-110 of 151) with videos related to

Sort By:
Pageof 16
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1996
Intensive therapy and autotransplant for patients with an incomplete response to front-line therapy for lymphomaH M Prince, M Crump, K Imrie, et al.
Leukemia & Lymphoma|December 29, 2004
A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphomaJ J Biagi, K E Herbert, C Smith, et al.
Bone Marrow Transplantation|March 14, 2003
Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastimL B To, J Bashford, S Durrant, et al.
Blood|September 6, 2001
Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemiaB J Huntly, A G Reid, A J Bench, et al.
Gene Therapy|April 30, 2010
Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotypeP Neeson, A Shin, K M Tainton, et al.
Cytotherapy|May 15, 2002
CliniMACS CD34-selected cells to support multiple cycles of high-dose therapyH M Prince, D Wall, D Rischin, et al.
Annals of the Rheumatic Diseases|October 14, 2011
Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohortSiri Lillegraven, Femke H M Prince, Nancy A Shadick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2015
Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphomaS Horwitz, B Coiffier, F Foss, et al.
British Journal of Haematology|March 1, 1996
The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groupsH M Prince, K Imrie, M Crump, et al.
Leukemia|February 7, 2013
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignanciesD J DeAngelo, A Spencer, K N Bhalla, et al.
Pageof 16